These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 36959063)

  • 21. Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas.
    Mawrin C; Sasse T; Kirches E; Kropf S; Schneider T; Grimm C; Pambor C; Vorwerk CK; Firsching R; Lendeckel U; Dietzmann K
    Clin Cancer Res; 2005 Jun; 11(11):4074-82. PubMed ID: 15930342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic
    Brastianos PK; Twohy EL; Gerstner ER; Kaufmann TJ; Iafrate AJ; Lennerz J; Jeyapalan S; Piccioni DE; Monga V; Fadul CE; Schiff D; Taylor JW; Chowdhary SA; Bettegowda C; Ansstas G; De La Fuente M; Anderson MD; Shonka N; Damek D; Carrillo J; Kunschner-Ronan LJ; Chaudhary R; Jaeckle KA; Senecal FM; Kaley T; Morrison T; Thomas AA; Welch MR; Iwamoto F; Cachia D; Cohen AL; Vora S; Knopp M; Dunn IF; Kumthekar P; Sarkaria J; Geyer S; Carrero XW; Martinez-Lage M; Cahill DP; Brown PD; Giannini C; Santagata S; Barker FG; Galanis E
    J Clin Oncol; 2023 Jan; 41(3):618-628. PubMed ID: 36288512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cucurbitacin I blocks cerebrospinal fluid and platelet derived growth factor-BB stimulation of leptomeningeal and meningioma DNA synthesis.
    Johnson MD; O'Connell MJ; Walter K
    BMC Complement Altern Med; 2013 Nov; 13():303. PubMed ID: 24188277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Landscape of genetic variants in sporadic meningiomas captured with clinical genomics.
    Leclair NK; Shen E; Wu Q; Wolansky L; Becker K; Li L; Bulsara KR
    Acta Neurochir (Wien); 2022 Sep; 164(9):2491-2503. PubMed ID: 35881312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SWI/SNF chromatin remodeling complex alterations in meningioma.
    Gill CM; Loewenstern J; Rutland JW; Arib H; Pain M; Umphlett M; Kinoshita Y; McBride RB; Bederson J; Donovan M; Sebra R; Fowkes M; Shrivastava RK
    J Cancer Res Clin Oncol; 2021 Nov; 147(11):3431-3440. PubMed ID: 33715086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in Molecular Classification and Therapeutic Opportunities in Meningiomas.
    Cordova C; Kurz SC
    Curr Oncol Rep; 2020 Jul; 22(8):84. PubMed ID: 32617743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meningioma: current updates on genetics, classification, and mouse modeling.
    Szulzewsky F; Thirimanne HN; Holland EC
    Ups J Med Sci; 2024; 129():. PubMed ID: 38571886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular genetics of meningiomas: Building the roadmap towards personalized therapy.
    Peyre M; Kalamarides M
    Neurochirurgie; 2018 Mar; 64(1):22-28. PubMed ID: 25245924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. mTOR Signaling and Potential Therapeutic Targeting in Meningioma.
    Pinker B; Barciszewska AM
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas.
    Strickland MR; Gill CM; Nayyar N; D'Andrea MR; Thiede C; Juratli TA; Schackert G; Borger DR; Santagata S; Frosch MP; Cahill DP; Brastianos PK; Barker FG
    J Neurosurg; 2017 Aug; 127(2):438-444. PubMed ID: 27885953
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diffuse midline skull base meningiomas: identification of a rare and aggressive subgroup of meningiomas.
    Peyre M; Feuvret L; Sanson M; Navarro S; Boch AL; Loiseau H; Kalamarides M
    J Neurooncol; 2017 Jul; 133(3):633-639. PubMed ID: 28536991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT.
    Jungwirth G; Warta R; Beynon C; Sahm F; von Deimling A; Unterberg A; Herold-Mende C; Jungk C
    Acta Neuropathol Commun; 2019 Aug; 7(1):140. PubMed ID: 31470906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.
    Beauchamp RL; James MF; DeSouza PA; Wagh V; Zhao WN; Jordan JT; Stemmer-Rachamimov A; Plotkin SR; Gusella JF; Haggarty SJ; Ramesh V
    Oncotarget; 2015 Jul; 6(19):16981-97. PubMed ID: 26219339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.
    Graillon T; Sanson M; Campello C; Idbaih A; Peyre M; Peyrière H; Basset N; Autran D; Roche C; Kalamarides M; Roche PH; Fuentes S; Tabouret E; Barrie M; Cohen A; Honoré S; Boucekine M; Baumstarck K; Figarella-Branger D; Barlier A; Dufour H; Chinot OL
    Clin Cancer Res; 2020 Feb; 26(3):552-557. PubMed ID: 31969329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
    James MF; Han S; Polizzano C; Plotkin SR; Manning BD; Stemmer-Rachamimov AO; Gusella JF; Ramesh V
    Mol Cell Biol; 2009 Aug; 29(15):4250-61. PubMed ID: 19451225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AKT1
    John P; Waldt N; Liebich J; Kesseler C; Schnabel S; Angenstein F; Sandalcioglu IE; Scherlach C; Sahm F; Kirches E; Mawrin C
    Neuropathol Appl Neurobiol; 2022 Feb; 48(2):e12780. PubMed ID: 34837233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments.
    Choy W; Kim W; Nagasawa D; Stramotas S; Yew A; Gopen Q; Parsa AT; Yang I
    Neurosurg Focus; 2011 May; 30(5):E6. PubMed ID: 21529177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.
    Brastianos PK; Horowitz PM; Santagata S; Jones RT; McKenna A; Getz G; Ligon KL; Palescandolo E; Van Hummelen P; Ducar MD; Raza A; Sunkavalli A; Macconaill LE; Stemmer-Rachamimov AO; Louis DN; Hahn WC; Dunn IF; Beroukhim R
    Nat Genet; 2013 Mar; 45(3):285-9. PubMed ID: 23334667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. KLF4
    von Spreckelsen N; Waldt N; Poetschke R; Kesseler C; Dohmen H; Jiao HK; Nemeth A; Schob S; Scherlach C; Sandalcioglu IE; Deckert M; Angenstein F; Krischek B; Stavrinou P; Timmer M; Remke M; Kirches E; Goldbrunner R; Chiocca EA; Huettelmaier S; Acker T; Mawrin C
    Acta Neuropathol Commun; 2020 Apr; 8(1):41. PubMed ID: 32245394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Life and death of molecular subclones in recurrent meningioma: A case study.
    Abele N; Kirches E; Sandalcioglu IE; Braunsdorf WEK; Mawrin C
    Clin Neuropathol; 2022; 41(4):174-178. PubMed ID: 35575414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.